About Kadimastem
Kadimastem is a company based in Ness Ziona (Israel) founded in 2009. The company has 11 employees as of December 31, 2024. Kadimastem operates in a competitive market with competitors including Jazz Pharmaceuticals, Biogen, Neurocrine, PTC Therapeutics and Biohaven Pharmaceutical, among others.
- Headquarter Ness Ziona, Israel
- Employees 11 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Kadimastem Ltd.
-
Annual Revenue
Not available
-
Net Profit
-$7.28 M (USD)-121.1as on Dec 31, 2024
-
EBITDA
-$1.39 M (USD)42as on Dec 31, 2024
-
Latest Funding Round
$5.01 M (USD), Post-IPO
Oct 25, 2021
-
Investors
European Union
& 8 more
-
Employee Count
11
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Kadimastem
Kadimastem is a publicly listed company on the TASE with ticker symbol KDST in Israel, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
People of Kadimastem
Unlock access to complete
Funding Insights of Kadimastem
Investors in Kadimastem
Kadimastem has secured backing from 9 investors, including venture fund, institutional, and angel investors. Prominent investors backing the company include European Union, Altshuler Shaham and Clover Wolf Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked | |
|
Diversified investment management services are provided to various clients.
|
Locked | Locked | Locked |
Investor details for Kadimastem
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Kadimastem
Investment portfolio details for Kadimastem
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Kadimastem
Detailed financials for Kadimastem
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Kadimastem Comparisons
Peer comparison for Kadimastem
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Kadimastem
Kadimastem operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, Biogen, Neurocrine, PTC Therapeutics and Biohaven Pharmaceutical, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| Locked | Locked | Locked |
Therapies for neurodegenerative and immunology disorders are developed.
|
|
| Locked | Locked | Locked |
Developer of small molecule therapeutics for endocrine and CNS disorders
|
|
| Locked | Locked | Locked |
Small molecule drugs for rare diseases are developed.
|
|
| Locked | Locked | Locked |
Therapies for neurological and neuropsychiatric diseases are developed.
|
|
| Locked | Locked | Locked |
Genetically engineered cell therapies are developed for multiple disorders.
|
Detailed competitors of Kadimastem
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Kadimastem
Complete news archive for Kadimastem
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Kadimastem
Kadimastem was founded in 2009 and raised its 1st funding round 7 years after it was founded.
Kadimastem is headquartered in Ness Ziona, Israel. It is registered at Ness Ziona, Central District, Israel.
As of Dec 31, 2024, the latest employee count at Kadimastem is 11.
Founded in 2009 and based in Ness Ziona, Israel, regenerative medicine efforts are directed toward developing and commercializing stem cell-based therapeutics for diabetes mellitus and amyotrophic lateral sclerosis. Proprietary technologies are used to differentiate stem cells into insulin-secreting beta cells and neural cells such as astrocytes and oligodendrocytes. Therapeutic programs are advanced for implantation to address disease progression, with collaborations focused on drug development using pluripotent stem cell-derived cells.
Kadimastem's top competitors include Jazz Pharmaceuticals, PTC Therapeutics and Neurocrine.
Yes, Kadimastem is publicly traded on TASE under the ticker symbol KDST.
Kadimastem has 9 investors. Key investors include European Union, Altshuler Shaham, Clover Wolf Capital, Alpha Capital Anstalt, and Yehuda Feinberg.
The ticker symbol of Kadimastem is KDST on TASE.